Rhumbline Advisers lifted its position in shares of Humana Inc (NYSE:HUM) by 4.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 236,325 shares of the insurance provider’s stock after purchasing an additional 10,475 shares during the period. Rhumbline Advisers owned 0.17% of Humana worth $62,862,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. HL Financial Services LLC raised its position in Humana by 19.4% during the 1st quarter. HL Financial Services LLC now owns 12,816 shares of the insurance provider’s stock worth $3,409,000 after purchasing an additional 2,086 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Humana by 6.4% in the 1st quarter. Parallel Advisors LLC now owns 1,714 shares of the insurance provider’s stock worth $456,000 after acquiring an additional 103 shares in the last quarter. Moors & Cabot Inc. raised its position in shares of Humana by 77.6% in the 1st quarter. Moors & Cabot Inc. now owns 1,318 shares of the insurance provider’s stock worth $350,000 after acquiring an additional 576 shares in the last quarter. Eagle Asset Management Inc. grew its stake in shares of Humana by 1.9% in the 1st quarter. Eagle Asset Management Inc. now owns 9,300 shares of the insurance provider’s stock valued at $2,473,000 after buying an additional 174 shares during the period. Finally, First National Bank of Omaha acquired a new stake in shares of Humana in the 1st quarter valued at about $4,636,000. Institutional investors own 92.64% of the company’s stock.
Several analysts have recently commented on HUM shares. Zacks Investment Research downgraded Humana from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Morgan Stanley set a $331.00 price target on Humana and gave the company a “buy” rating in a research note on Thursday, May 2nd. Citigroup cut their price target on Humana from $397.00 to $362.00 and set a “buy” rating for the company in a research note on Thursday, February 7th. Credit Suisse Group cut their price target on Humana from $390.00 to $352.00 and set an “outperform” rating for the company in a research note on Thursday, February 7th. Finally, Barclays cut their target price on Humana from $351.00 to $327.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 17th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $337.26.
HUM stock traded down $1.01 during midday trading on Wednesday, reaching $251.04. 1,064,674 shares of the company’s stock traded hands, compared to its average volume of 1,579,667. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.65 and a quick ratio of 1.65. Humana Inc has a 52 week low of $225.65 and a 52 week high of $355.88. The stock has a market capitalization of $35.56 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 1.08 and a beta of 0.88.
Humana (NYSE:HUM) last issued its earnings results on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.30 by $0.18. Humana had a net margin of 2.99% and a return on equity of 20.77%. The business had revenue of $16.11 billion for the quarter, compared to analysts’ expectations of $15.67 billion. During the same quarter in the previous year, the firm posted $3.36 EPS. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. Equities research analysts anticipate that Humana Inc will post 17.57 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.55 per share. The ex-dividend date is Thursday, June 27th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.88%. Humana’s dividend payout ratio (DPR) is currently 15.12%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Article: Trading Ex-Dividend
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.